Ni Zhang , Xiangyu Zhang , Tinghao Yan , Fen Liu , Xinchen Tian , Changlin Ma , Huapeng Lin , Yiming Zhang , Lingli Hao , Jiaqi Zhang , Qingxia Xu , Qingbin Liu , Shulong Jiang
{"title":"染色体外DNA (ecDNA)通过染色体1q21衍生的PIP5K1A癌基因的高拷贝扩增驱动肝细胞癌恶性","authors":"Ni Zhang , Xiangyu Zhang , Tinghao Yan , Fen Liu , Xinchen Tian , Changlin Ma , Huapeng Lin , Yiming Zhang , Lingli Hao , Jiaqi Zhang , Qingxia Xu , Qingbin Liu , Shulong Jiang","doi":"10.1016/j.canlet.2025.218004","DOIUrl":null,"url":null,"abstract":"<div><div>Extrachromosomal circular DNA (eccDNA) drives oncogene amplification in multiple malignancies, yet its landscape and clinical relevance in hepatocellular carcinoma (HCC) remain poorly characterized. Here, we performed Circle-seq and RNA-seq on six pairs of HCC tumors and adjacent non-tumor tissues, identifying a 3 Mb extrachromosomal DNA (ecDNA) from chromosome 1q21 in 50 % tumor samples. This ecDNA contained multiple genes, but functional analysis prioritized <em>PIP5K1A</em> due to its central role in <em>PI3K/AKT</em> signaling and association with poor prognosis. The extrachromosomal localization of <em>PIP5K1A</em> was validated through outward PCR, inward PCR, Sanger sequencing, and fluorescence <em>in situ</em> hybridization (FISH) assays. Kaplan-Meier (KM) analysis demonstrated that elevated <em>PIP5K1A</em> expression was associated with an unfavorable prognosis in patients with HCC. <em>In vivo</em> and <em>in vitro</em> assays revealed that ecDNA-driven <em>PIP5K1A</em> amplification enhanced HCC proliferation, migration, and apoptosis resistance. Our study provides a genome-wide eccDNA profiling of HCC, implicating 1q21 ecDNA and <em>PIP5K1A</em> as prognostic markers and therapeutic targets, offering insights into HCC treatment strategies.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"633 ","pages":"Article 218004"},"PeriodicalIF":10.1000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Extrachromosomal DNA (ecDNA) drives hepatocellular carcinoma malignancy through high-copy amplification of chromosome 1q21-derived PIP5K1A oncogene\",\"authors\":\"Ni Zhang , Xiangyu Zhang , Tinghao Yan , Fen Liu , Xinchen Tian , Changlin Ma , Huapeng Lin , Yiming Zhang , Lingli Hao , Jiaqi Zhang , Qingxia Xu , Qingbin Liu , Shulong Jiang\",\"doi\":\"10.1016/j.canlet.2025.218004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Extrachromosomal circular DNA (eccDNA) drives oncogene amplification in multiple malignancies, yet its landscape and clinical relevance in hepatocellular carcinoma (HCC) remain poorly characterized. Here, we performed Circle-seq and RNA-seq on six pairs of HCC tumors and adjacent non-tumor tissues, identifying a 3 Mb extrachromosomal DNA (ecDNA) from chromosome 1q21 in 50 % tumor samples. This ecDNA contained multiple genes, but functional analysis prioritized <em>PIP5K1A</em> due to its central role in <em>PI3K/AKT</em> signaling and association with poor prognosis. The extrachromosomal localization of <em>PIP5K1A</em> was validated through outward PCR, inward PCR, Sanger sequencing, and fluorescence <em>in situ</em> hybridization (FISH) assays. Kaplan-Meier (KM) analysis demonstrated that elevated <em>PIP5K1A</em> expression was associated with an unfavorable prognosis in patients with HCC. <em>In vivo</em> and <em>in vitro</em> assays revealed that ecDNA-driven <em>PIP5K1A</em> amplification enhanced HCC proliferation, migration, and apoptosis resistance. Our study provides a genome-wide eccDNA profiling of HCC, implicating 1q21 ecDNA and <em>PIP5K1A</em> as prognostic markers and therapeutic targets, offering insights into HCC treatment strategies.</div></div>\",\"PeriodicalId\":9506,\"journal\":{\"name\":\"Cancer letters\",\"volume\":\"633 \",\"pages\":\"Article 218004\"},\"PeriodicalIF\":10.1000,\"publicationDate\":\"2025-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0304383525005749\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer letters","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0304383525005749","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Extrachromosomal DNA (ecDNA) drives hepatocellular carcinoma malignancy through high-copy amplification of chromosome 1q21-derived PIP5K1A oncogene
Extrachromosomal circular DNA (eccDNA) drives oncogene amplification in multiple malignancies, yet its landscape and clinical relevance in hepatocellular carcinoma (HCC) remain poorly characterized. Here, we performed Circle-seq and RNA-seq on six pairs of HCC tumors and adjacent non-tumor tissues, identifying a 3 Mb extrachromosomal DNA (ecDNA) from chromosome 1q21 in 50 % tumor samples. This ecDNA contained multiple genes, but functional analysis prioritized PIP5K1A due to its central role in PI3K/AKT signaling and association with poor prognosis. The extrachromosomal localization of PIP5K1A was validated through outward PCR, inward PCR, Sanger sequencing, and fluorescence in situ hybridization (FISH) assays. Kaplan-Meier (KM) analysis demonstrated that elevated PIP5K1A expression was associated with an unfavorable prognosis in patients with HCC. In vivo and in vitro assays revealed that ecDNA-driven PIP5K1A amplification enhanced HCC proliferation, migration, and apoptosis resistance. Our study provides a genome-wide eccDNA profiling of HCC, implicating 1q21 ecDNA and PIP5K1A as prognostic markers and therapeutic targets, offering insights into HCC treatment strategies.
期刊介绍:
Cancer Letters is a reputable international journal that serves as a platform for significant and original contributions in cancer research. The journal welcomes both full-length articles and Mini Reviews in the wide-ranging field of basic and translational oncology. Furthermore, it frequently presents Special Issues that shed light on current and topical areas in cancer research.
Cancer Letters is highly interested in various fundamental aspects that can cater to a diverse readership. These areas include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis, and chemoprevention. The journal actively focuses on experimental therapeutics, particularly the advancement of targeted therapies for personalized cancer medicine, such as metronomic chemotherapy.
By publishing groundbreaking research and promoting advancements in cancer treatments, Cancer Letters aims to actively contribute to the fight against cancer and the improvement of patient outcomes.